Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BCLI | US
0.25
11.47%
Healthcare
Biotechnology
30/06/2024
17/10/2024
2.43
2.18
2.68
2.18
Brainstorm Cell Therapeutics Inc. a biotechnology company engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company through its NurOwn proprietary cell therapy platform leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors modulate neuroinflammatory and neurodegenerative disease processes promote neuronal survival and enhance neurological function. It is developing NurOwn which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York New York.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
113.0%1 month
112.2%3 months
97.4%6 months
108.4%-
-
65.82
-0.27
0.17
-1.70
-
-
-16.04M
12.92M
12.92M
-
-
-
-
-1.12K
5.98
2.48
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.74
Range1M
3.50
Range3M
3.51
Rel. volume
3.89
Price X volume
674.68K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
IMNN | IMNN | Biotechnology | 0.9787 | 14.09M | -2.12% | n/a | 37.13% |
Aytu BioScience Inc | AYTU | Biotechnology | 2.29 | 14.08M | 0.11% | n/a | 54.59% |
Cingulate Inc. Common Stock | CING | Biotechnology | 4.49 | 13.67M | 2.05% | n/a | 10.72% |
NRXP | NRXP | Biotechnology | 1.265 | 13.60M | 2.85% | n/a | -46.73% |
Tenax Therapeutics Inc | TENX | Biotechnology | 3.9 | 13.60M | 2.63% | n/a | 3.14% |
Apollomics Inc. Class A Ordinary Shares | APLM | Biotechnology | 0.1232 | 13.55M | -1.36% | n/a | 21.43% |
Edesa Biotech Inc | EDSA | Biotechnology | 4.1 | 13.42M | 0.74% | n/a | 1.35% |
KTRA | KTRA | Biotechnology | 0.2154 | 11.99M | -6.31% | n/a | 0.00% |
DOMH | DOMH | Biotechnology | 1.88 | 11.80M | -3.09% | n/a | 7.66% |
BioRestorative Therapies Inc | BRTX | Biotechnology | 1.6815 | 11.64M | -2.80% | n/a | 0.77% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.70 | 0.53 | Cheaper |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | 65.82 | 15.30 | Expensive |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 97.39 | 72.92 | Riskier |
Debt to Equity | -0.27 | -1.24 | Expensive |
Debt to Assets | 0.17 | 0.25 | Cheaper |
Market Cap | 12.92M | 3.78B | Emerging |